Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus YUVEZZI.
LATANOPROSTENE BUNOD vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2α analog. It is hydrolyzed by esterases in the eye to latanoprost acid and nitric oxide. Latanoprost acid increases uveoscleral outflow of aqueous humor via FP receptor agonism, while NO enhances trabecular meshwork outflow via soluble guanylate cyclase activation.
YUVEZZI is not a recognized drug. No mechanism available.
One drop (approximately 1.5 mcg) in the affected eye(s) once daily in the evening.
150 mg orally twice daily
None Documented
None Documented
The terminal elimination half-life of latanoprostene bunod is approximately 17 minutes for the active metabolite (latanoprost acid) after topical ocular administration. This short half-life reflects rapid systemic clearance, consistent with once-daily dosing for intraocular pressure reduction.
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine."
Clinical Note
moderateTerminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
The primary route of elimination is via the kidneys, with approximately 88% of the dose excreted in urine as metabolites; fecal excretion accounts for about 6%, and the remainder is excreted via other routes. Renal excretion of unchanged drug is minimal.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
Balsalazide + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Balsalazide."